Company profile: Cardiol Therapeutics
1.1 - Company Overview
Company description
- Provider of cannabidiol-based therapies for heart disease, including CardiolRx, an oral solution in clinical development to inhibit inflammatory pathways; CRD-38, a subcutaneous formulation for heart failure aiming to improve pharmacokinetics and therapeutic efficacy; and Phase II studies MAvERIC-Pilot (recurrent pericarditis) and ARCHER (acute myocarditis) evaluating safety, tolerability, efficacy, and impact on myocardial recovery.
Products and services
- CardiolRx: An oral solution of cannabidiol in clinical development for heart diseases, engineered to inhibit inflammatory pathways to address cardiac inflammation
- ARCHER Study: A Phase II multi-national study assessing the safety, tolerability, and effect of CardiolRx on myocardial recovery in acute myocarditis patients
- CRD-38: A subcutaneously administered formulation of cannabidiol intended for heart failure treatment, aiming to improve pharmacokinetics and therapeutic efficacy
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cardiol Therapeutics
HeartWare
HQ: United States
Website
- Description: Provider of small implantable heart pumps and ventricular assist devices for treating advanced heart failure, offering the HeartWare Ventricular Assist System with LVAD/blood pump, patient accessories, and surgical tools. Products include the Medtronic HVAD System for less-invasive thoracotomy, destination therapy and bridge to transplant, plus HVAD Waveforms, controller logfiles, Autologs, and HVAD patient resources.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full HeartWare company profile →
Medos Medizintechnik
HQ: Germany
Website
- Description: Provider of medical devices for cardiac surgery, extracorporeal membrane oxygenation, and ventricle assist devices, offering VAD cannulae, X-Flow, DELTASTREAM, HILITE, HILITE Reservoirs, and tubing sets (machine-sets, table-sets).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medos Medizintechnik company profile →
Acesion Pharma
HQ: Denmark
Website
- Description: Provider of medical drugs for the treatment of atrial fibrillation, developing therapies that inhibit a heart cell ion channel. Offerings include AP30663, an intravenous drug for acute cardioversion to sinus rhythm with demonstrated efficacy in clinical trials, and AP31969, an oral drug for maintenance of sinus rhythm in patients with atrial fibrillation, currently in clinical development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acesion Pharma company profile →
VentureMed Group
HQ: United States
Website
- Description: Provider of vessel preparation systems and dynamic lesion engagement technology enabling interventionalists to treat peripheral artery disease and arteriovenous fistulas and grafts. Offerings include the FLEX Vessel Prep System using micro-incisions to modify plaque and stenosis and Dynamic Treatment Technology to improve vessel compliance and luminal gain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full VentureMed Group company profile →
Applied Therapeutics
HQ: United States
Website
- Description: Provider of drug development targeting molecules/pathways in fatal or debilitating diseases, with programs: govorestat for Galactosemia (pediatric Phase 3 completed; MAA validated; NDA accepted; PDUFA date set), SORD Deficiency (positive pilot; ongoing Phase 3), PMM2-CDG (Phase 2-ready; Expanded Access), AT-001 for Diabetic Cardiomyopathy/Peripheral Neuropathy (Phase 3), and AT-003 for Diabetic Retinopathy (Phase 1-ready).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Applied Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cardiol Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cardiol Therapeutics
2.2 - Growth funds investing in similar companies to Cardiol Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cardiol Therapeutics
4.2 - Public trading comparable groups for Cardiol Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →